Figures & data
Figure 1. Structures of AAZ, SLC-0111, A–C, and the designed quinazoline derivatives (2–20) as CAIs.
![Figure 1. Structures of AAZ, SLC-0111, A–C, and the designed quinazoline derivatives (2–20) as CAIs.](/cms/asset/9cf0a89e-8cd4-4ed5-aa19-9066226323f5/ienz_a_1742117_f0001_c.jpg)
Table 1. Inhibition data of hCA isoforms hCA I, II, IX and XII for sulphonamides using AAZ as standard drug.
Figure 2. Docking modes of active compounds 17 and 20 in the binding pockets of CA isoenzyme IX (PDB 5FL4). Predicted binding mode of compounds 17 (2D and 3D in upper panel), and 20 (2D and 3D in lower panel) with the hCA-IX target.
![Figure 2. Docking modes of active compounds 17 and 20 in the binding pockets of CA isoenzyme IX (PDB 5FL4). Predicted binding mode of compounds 17 (2D and 3D in upper panel), and 20 (2D and 3D in lower panel) with the hCA-IX target.](/cms/asset/ef86295e-0ef6-4f43-affa-4b8fa64392bf/ienz_a_1742117_f0002_c.jpg)